Lilly Medical Affairs
Developed under the direction and sponsorship of Lilly Medical Affairs and is intended for US healthcare professionals only.
Metastatic Breast Cancer
Lilly Medical Affairs
A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC
FEATURING
Joyce O’Shaughnessy
- 45 views
- July 24, 2024
Lilly Medical Affairs
CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC
FEATURING
Joyce O’Shaughnessy
- 67 views
- July 24, 2024
Lilly Medical Affairs
Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and Sequencing
FEATURING
Joyce O’Shaughnessy
- 71 views
- July 24, 2024
Lilly Medical Affairs
Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- MBC
FEATURING
Komal Jhaveri
- 75 views
- July 24, 2024
Lilly Medical Affairs
SERDS: Relevance and Role in Current & Future Treatments for HR+, HER2- MBC
FEATURING
Komal Jhaveri
- 59 views
- July 24, 2024
